Similarly, dinaciclib is a highly potent CDK inhibitor with selectivity for CDK1, CDK2, CDK5, and CDK9 [20] in phase III clinical trials for the treatment of refractory chronic lymphocytic leukemia. This evidence concerns the gene CDK2 and B-cell chronic lymphocytic leukemia.